Characterization of Hemodynamic Events Following Intravascular Infusion of Recombinant Adenovirus Reveals Possible Solutions for Mitigating Cardiovascular Responses

Abstract

Intravascular administration of recombinant adenovirus (rAd) in cancer patients has been well tolerated. However, dose-limiting hemodynamic responses associated with suppression of cardiac output have been observed at doses of 7.5 x 10(13) particles. While analysis of hemodynamic responses induced by small-molecule pharmaceuticals is well established, little is known about the cardiovascular effects of rAd. Telemetric cardiovascular (CV) monitoring in mice was utilized to measure hemodynamic events following intravascular rAd administration. Electrocardiogram analysis revealed a block in the SA node 3-4 min postinfusion, resulting in secondary pacemaking initiated at the AV node. This was associated with acute bradycardia, reduced blood pressure, and hypothermia followed by gradual recovery. Adenovirus-primed murine sera with high neutralizing antibody (nAb) titers could inhibit CV responses, whereas human sera with equivalent nAb titers induced by natural infection were, surprisingly, not inhibitory. Interestingly, repeat dosing within 2-4 h of the primary injection resulted in desensitization, resembling tachyphylaxis, for subsequent CV responses. Last, depletion of Kupffer cells prior to rAd infusion precluded induction of CV responses. These inhibitory effects suggest that rAd interactions with certain cells of the reticular endothelial system are associated with induction of CV responses. Significantly, these studies may provide insight into management of acute adverse effects following rAd systemic delivery, enabling a broadening of therapeutic index.

Factors influencing retention of adenovirus within tumours following direct intratumoural injection

“…15,23,[28][29][30][31] Although IT injection of adenovirus vectors should reduce the overall likelihood of inflammatory responses, our data suggest that the use of larger volumes of injectate may give substantial dissemination of virus into the systemic circulation. This might account for the incidences of flu-like symptoms widely reported in clinical trials.…”

Progress and prospects: gene therapy for genetic diseases with helper-dependent adenoviral vectors

“…21 However, the interaction between Ad and KCs does appear to trigger a series of cardiovascular responses, including heart rhythm disturbance, a decrease in blood pressure and ischemic events after systemic high-dose injection. 23 Toll-like receptors (TLRs) are crucial components in pathogen recognition processes and are emerging as important players in Ad-mediated acute toxicity. [24][25][26][27][28][29][30] Upon TLR activation, an increased production of cytokines triggers dendritic cell maturation and development of functional T-and B-cell responses aimed at inhibiting pathogen replication.…”

Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo

“…Much of the cytokine response is initiated by innate pattern recognition proteins, such as TLR9, which can recognize Ad genomic DNA (4,8,42,45,69). Phagocytic cells in the liver and spleen also play an important role in the innate response to systemically delivered Ad vectors (4,37,38,54,56,68). Likewise, complement is an ancient innate defense system that detects and responds to pathogens, including viruses (52).…”